이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Single-Center, Randomized Controlled Trial of Transcoronary Radiofrequency Ablation Versus Transcoronary Alcohol Ablation for Hypertrophic Obstructive Cardiomyopathy

2026년 11월 16일 업데이트: Ligang Ding

Patients with hypertrophic obstructive cardiomyopathy (HOCM) require septal reduction therapy to relieve left ventricular outflow tract obstruction (LVOTO). Septal myectomy is an open surgical procedure that resects hypertrophied septal myocardium to reduce outflow tract obstruction. However, it is associated with relatively substantial trauma. Some patients cannot tolerate surgery due to comorbidities or decline open-chest surgery.

Transcoronary alcohol ablation is a classic minimally invasive septal reduction therapy with a clinical history of nearly 30 years. Alcohol ablation induces myocardial injury via a chemical agent to reduce septal hypertrophy, widen the left ventricular outflow tract, lower the systolic pressure gradient, and improve clinical symptoms. It serves as a minimally invasive alternative to surgery. Nevertheless, the efficacy of this technique is highly dependent on the anatomical features of septal branches. Suboptimal outcomes may occur in some patients owing to variable septal branch anatomy. In addition, due to the high myocardial permeability of alcohol, atrioventricular block occurs in approximately 20% of patients after the procedure.

In recent years, transcoronary radiofrequency ablation has emerged as a novel minimally invasive septal reduction approach in clinical practice. For radiofrequency ablation, a microcatheter is advanced over a coronary guidewire into the septal branch. The proximal end of the guidewire is connected to a radiofrequency ablation generator, and myocardial ablation is delivered around the guidewire tip. Occlusion of the septal branch may further potentiate the ablative effect. This technique is less limited by anatomical variations of septal branches, features a shorter learning curve, and may have less impact on the conduction system. Compared with alcohol ablation, it enables more precise ablation with potentially superior safety. Both minimally invasive strategies achieve an obstruction relief rate exceeding 90%. To date, head-to-head data comparing the efficacy and safety profiles of these two minimally invasive therapies remain absent. Therefore, this randomized controlled trial is designed to compare the efficacy and safety of transcoronary alcohol ablation versus transcoronary radiofrequency ablation for hypertrophic obstructive cardiomyopathy.

You will be randomized in a 1:1 ratio to either the transcoronary alcohol ablation group or the transcoronary radiofrequency ablation group using a block randomization schedule. The probability of assignment to either group is 50%.

After randomization, cardiopulmonary exercise testing data, laboratory results and echocardiographic data will be collected at baseline, and the impact of cardiomyopathy on your quality of life will be assessed. Procedures in both groups will be performed by designated operators of the study team following standardized protocols. You will be blinded to the assigned treatment. In both groups, SonoVue will be injected into the coronary septal branch intraoperatively, and transthoracic echocardiography will be used to confirm that the ablation target is the critical site responsible for obstruction to ensure precise treatment. In the alcohol ablation group, 2-3 mL of absolute alcohol will be injected into the septal branch. In the radiofrequency ablation group, the guidewire will be connected to the radiofrequency generator; ablation energy will be set at 30-40 W, with 3 ablation applications of 30 seconds each at a single target site. Intraoperative electrocardiogram, heart rate, blood pressure and symptoms will be closely monitored, and the pressure gradient will be measured in real time using catheters and ultrasound. All patients will receive standardized medical therapy after the procedure. You will attend an outpatient follow-up visit at 3 months post-procedure, where repeat cardiopulmonary exercise testing, laboratory tests and echocardiography will be performed, and the post-procedure impact of cardiomyopathy on your quality of life will be re-evaluated. The primary endpoint of this study is the improvement in peak oxygen consumption on cardiopulmonary exercise testing at 3 months after treatment. No blood or tissue samples will be collected or stored for this study.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

80

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100037
        • 모병
        • Fuwai Hospital, Chinese Academy of Medical Sciences
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • 1. Age > 18 years; 2. Diagnosis of hypertrophic obstructive cardiomyopathy (HOCM), with resting LVOTG > 50 mmHg measured by echocardiography or cardiac catheterization; 3. Persistent symptoms despite treatment with maximally tolerated doses of beta-blockers or calcium channel blockers (CCBs); 4. New York Heart Association (NYHA) functional class II or higher; 5. Echocardiographic confirmation that the obstruction originates from the interventricular septum at the left ventricular outflow tract; 6. Suitable septal branch visualized on coronary angiography, with contrast echocardiography confirming its perfusion territory corresponds to the target ablation site; 7. Interventricular septal thickness < 30 mm; 8. High surgical risk or explicit patient refusal of septal myectomy; 9. Ability to understand the study purpose, voluntary participation, and provision of written informed consent.

Exclusion Criteria:

  • Patients with severe mitral regurgitation secondary to organic mitral valve disease or other cardiac structural abnormalities requiring surgical intervention; Patients with significant stenosis of the left anterior descending coronary artery requiring percutaneous coronary intervention; Patients with bradyarrhythmia who have an indication for permanent pacemaker implantation; Patients with prior history of septal reduction therapy; Patients receiving myosin inhibitor therapy; Patients with severe hepatic or renal dysfunction; Patients with contraindications to coronary angiography and percutaneous interventional procedures; Patients with severe heart failure or cardiogenic shock who cannot maintain a supine position; Patients with a history of anaphylactic shock induced by contrast media; Patients considered ineligible for enrollment for other reasons at the investigator's discretion; Patients with pre-existing complete left bundle branch block at baseline.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: transcoronary radiofrequency ablation

Both groups received SonoVue injection into the septal branch, and transthoracic echocardiography was used to confirm that the ablation site was the critical lesion responsible for obstruction. In the TCRFA group, a microcatheter was advanced over a coronary guidewire into the septal branch; the proximal end of the guidewire was connected to a radiofrequency ablation generator, and myocardial ablation was delivered around the guidewire tip. The ablation power was set at 30-40 W, with three applications of 30 seconds each at a single target site. Intraoperatively, electrocardiogram, heart rate, blood pressure and symptoms were closely monitored in both groups, and the left ventricular outflow tract gradient (LVOTG) was measured in real time via catheter and ultrasound. For patients in the TCRFA group whose post-treatment LVOTG failed to meet the criteria for obstruction relief, supplementary endocardial ablation would be performed intraoperatively to achieve the target reduction of LVO

Both groups received SonoVue injection into the septal branch, and transthoracic echocardiography was used to confirm that the ablation site was the critical lesion responsible for obstruction. In the TCRFA group, a microcatheter was advanced over a coronary guidewire into the septal branch; the proximal end of the guidewire was connected to a radiofrequency ablation generator, and myocardial ablation was delivered around the guidewire tip. The ablation power was set at 30-40 W, with three applications of 30 seconds each at a single target site. Intraoperatively, electrocardiogram, heart rate, blood pressure and symptoms were closely monitored in both groups, and the left ventricular outflow tract gradient (LVOTG) was measured in real time via catheter and ultrasound. For patients in the TCRFA group whose post-treatment LVOTG failed to meet the criteria for obstruction relief, supplementary endocardial ablation would be performed intraoperatively to achieve the target reduction of LVOT

다른 이름들:
  • TCRFA
활성 비교기: transcoronary alcohol ablation

SonoVue is injected into the septal branch, and transthoracic echocardiography is used to confirm that the ablation site is the critical site causing obstruction. In the ASA group, 2-3 mL of absolute alcohol is injected into the septal branch. Intraoperatively, the patient's electrocardiogram, heart rate, blood pressure and symptoms are closely monitored, and LVOTG is measured in real time using catheters and ultrasound.

SonoVue is injected into the septal branch, and transthoracic echocardiography is used to confirm that the ablation site is the critical site causing obstruction. In the ASA group, 2-3 mL of absolute alcohol is injected into the septal branch. Intraoperatively, the patient's electrocardiogram, heart rate, blood pressure and symptoms are closely monitored, and LVOTG is measured in real time using catheters and ultrasound.

다른 이름들:
  • asa

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
absolute improvement in peak VO₂
기간: baseline,3 months

Cardiopulmonary exercise testing is performed at baseline and at 3 months after the procedure to measure peak VO₂. The absolute improvement in peak VO₂ is defined as the post-procedure value minus the baseline value.

baseline,3 months
ncidence of new-onset complete left or right bundle branch block and/or permanent pacemaker implantation
기간: baseline,3 months

The incidence of new-onset complete left bundle branch block, complete right bundle branch block, and/or permanent pacemaker implantation occurring from the time of the index procedure up to the 3-month post-procedure follow-up.

baseline,3 months

2차 결과 측정

결과 측정
측정값 설명
기간
Intraprocedural immediate reduction of LVOTG meeting criteria for obstruction relief
기간: Intraoperatively

Proportion of participants with immediate intraprocedural LVOTG reduction that satisfies the predefined criteria for relief of left ventricular outflow tract obstruction.

Intraoperatively
Response rate of peak VO₂ at 3 months post-procedure
기간: Baseline and 3 months after the procedure

Response rate is defined as the proportion of participants achieving a predefined improvement in peak VO₂ measured by cardiopulmonary exercise testing at 3 months post-procedure versus baseline.

Baseline and 3 months after the procedure
Reduction of LVOTG meeting obstruction relief criteria at 3 months post-procedure
기간: Baseline and 3 months after the procedure

Proportion of participants whose LVOTG reduction meets the predefined obstruction relief criteria at 3-month follow-up.

Baseline and 3 months after the procedure
Absolute reduction of basal septal thickness
기간: Baseline and 3 months after the procedure

Absolute difference in basal interventricular septal thickness between baseline and 3 months post-procedure, assessed by echocardiography.

Baseline and 3 months after the procedure
6-minute walk test distance
기간: Baseline and 3 months after the procedure

Distance covered during the 6-minute walk test at baseline and at 3 months post-procedure.

Baseline and 3 months after the procedure
Canadian Cardiovascular Society (CCS) Angina Grade
기간: Baseline and 3 months after the procedure

Change in Canadian Cardiovascular Society angina grade from baseline to 3 months post-procedure.

Baseline and 3 months after the procedure
Quality of life score
기간: Baseline and 3 months after the procedure

Change in generic quality-of-life score from baseline to 3 months post-procedure.

Baseline and 3 months after the procedure
Kansas City Cardiomyopathy Questionnaire (KCCQ) score
기간: Baseline and 3 months after the procedure

Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score from baseline to 3 months post-procedure.

Baseline and 3 months after the procedure
Improvement in New York Heart Association (NYHA) functional class
기간: Baseline and 3 months after the procedure

Proportion of participants with improvement in New York Heart Association functional class at 3 months post-procedure compared with baseline.

Baseline and 3 months after the procedure

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 16일

기본 완료 (추정된)

2027년 9월 30일

연구 완료 (추정된)

2027년 12월 31일

연구 등록 날짜

최초 제출

2026년 11월 16일

QC 기준을 충족하는 최초 제출

2026년 11월 16일

처음 게시됨 (실제)

2026년 11월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 16일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2025-2753

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant data will not be shared to ensure patient confidentiality and comply with local institutional data protection policies.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .